Business
Rallybio to Present at Upcoming Investor Conferences in November
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the
About this update from Rallybio Corporation
[{"type":"text","content":" NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:\n\n\n\nStifel 2023 Healthcare Conference in New York, NY on Wednesday, November 15, 2023. Steve Uden, M.D., Chief Executive Officer will present a corporate overview at 3:00 p.m. EST.\n\n\n\n6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Tuesday, November 28, 2023. Steve Uden. M.D., Chief Executive Officer will participate in a fireside chat at 7:30 a.m. EST.\n\n\n\nLive webcasts of both presentations will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.\n\n\nAbout Rallybio\n\n\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.\n\n\nRallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231028440323/en/\n\nInvestor Contacts\nAmi Bavishi\nHead of Investor Relations and Communications\n475-47-RALLY (Ext. 282)\[email protected]\n\n\nHannah Deresiewicz\nStern Investor Relations, Inc.\n212-362-1200\[email protected]\n\n\nMedia Contact\nJorge Gaeta\nMission North\n(516) 43...